Dermata Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Balance Sheet Details

9 Months Ended

Sep. 30, 2021

3. Balance Sheet Details

The following provides certain balance sheet details:

	September 30,			December 31,
	2021			2020

Prepaid expenses and other current assets
Prepaid insurance	$	1,082,446		$	68,003
Prepaid research and development costs		-			7,050
Total prepaid expenses and other current assets	$	1,082,446		$	75,053

Fixed assets
Furniture and office equipment	$	59,382		$	59,382
Computer equipment		17,225			17,225
		76,607			76,607
Less: accumulated depreciation and amortization		(76,607	)		(76,607	)
Total fixed assets, net	$	-		$	-

Accrued and other current liabilities
Accrued interest payable	$	-		$	49,169
Accrued compensation and benefits		424,569			84,308
Accrued research and development costs		800			-
Total accrued and other current liabilities	$	425,369		$	133,477